Capsulution NanoScience Starts New Feasibility Studies
News Oct 12, 2005
Capsulution NanoScience AG has commenced two feasibility studies in the area of pharmaceutical formulation (drug delivery) that have been commissioned by two renowned industrial clients.
Using the proprietary LBL-Technology, both studies aim at increasing the bioavailability of several new chemical entities (NCEs) in the human body.
Particularly the transport of water insoluble compounds like a wide range of drug candidates in the development pipelines of pharmaceutical companies will be optimized during the studies.
“We are receiving a great deal of interest from drug manufacturers in our patented technology,” said Maria González Ferreiro, Director Business Development of Capsulution NanoScience AG.
“Both studies are aimed at close adaptations of our patented LBL-Technology® to the requirements of the pharmaceutical industry.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018